Anderson Raymond's Form 4/A amendment
AmendedMonopar Therapeutics (MNPR) · filed Aug 28, 2026
- Accession no.
- 0001437749-26-029228
- Filed
- Aug 28, 2026, 7:41 PM ET
- Trade date
- Aug 25, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Aug 27, 2026
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $351.8K. It was filed 3 days after the trade.
This amendment replaces 0001437749-26-029115 (filed Aug 27, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anderson RaymondCIK 0001362489 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Common Stock | MOption exerciseAcquired | +1,402 | $30.00 | +$42,060 | 6,775 | Direct | |
| Aug 25, 2026 | Common Stock | MOption exerciseAcquired | +1,740 | $30.00 | +$52,200 | 8,515 | Direct | |
| Aug 25, 2026 | Common Stock | SSaleDisposed | −694 | $110.04F4 | −$76,367.76 | 7,821 | Direct | |
| Aug 25, 2026 | Common Stock | SSaleDisposed | −646 | $111.07F5 | −$71,751.22 | 7,175 | Direct | |
| Aug 25, 2026 | Common Stock | SSaleDisposed | −1,802 | $113.05F6 | −$203,716.1 | 5,373 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Common Stock | MOption exerciseAcquired | +1,402 | $0.00 | $0 | 2,803 | Direct | |
| Aug 25, 2026 | Common Stock | MOption exerciseAcquired | +1,740 | $0.00 | $0 | 3,480 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.
- F2
On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.
- F3
On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
Referenced by the price of 1 transaction in Table I.
Remarks
On August 27, 2026, the reporting person filed a Form 4, which inadvertently omitted two option exercises that were made prior to the reporting person's sale of shares of common stock. Both the option exercises and the sales of common stock were effected pursuant to a Rule 10b5-1 Plan. The prior Form 4 also did not account for Monopar Therapeutics Inc.'s 5 to 1 reverse stock split of its common stock, which was effected August 12, 2024 (the "Reverse Stock Split"). The amount of securities reported on this amended Form 4 have been adjusted to reflect the Reverse Stock Split.